Header

UZH-Logo

Maintenance Infos

The changing landscape of pediatric low-grade gliomas: clinical challenges and emerging therapies


Guerreiro Stucklin, Ana S; Tabori, Uri; Grotzer, Michael A (2016). The changing landscape of pediatric low-grade gliomas: clinical challenges and emerging therapies. Neuropediatrics, 47(2):70-83.

Abstract

Pediatric low-grade gliomas (PLGGs) are the most common brain tumors in children. Though histologically benign and associated with excellent outcome, patients with unresectable lesions--mostly young children with midline tumors--experience multiple progressions and are at increased risk for long-term neurological sequelae. PLGGs in children with underlying genetic predisposition syndromes--especially neurofibromatosis type 1 and tuberous sclerosis--have a distinct natural history and biology with important treatment implications. Given the complexity of medical issues, optimal management requires a large network of health care providers; treatment decisions must address both tumor control and potential side effects of the therapy. Current treatment strategies often fail to induce sustained tumor regression and many children require several lines of therapy, highlighting the need for novel therapies. Here, we review the current management of PLGG and discuss how new molecular targets--in particular alterations of the Ras/MAPK pathway--are rapidly changing our approach to PLGG.

Abstract

Pediatric low-grade gliomas (PLGGs) are the most common brain tumors in children. Though histologically benign and associated with excellent outcome, patients with unresectable lesions--mostly young children with midline tumors--experience multiple progressions and are at increased risk for long-term neurological sequelae. PLGGs in children with underlying genetic predisposition syndromes--especially neurofibromatosis type 1 and tuberous sclerosis--have a distinct natural history and biology with important treatment implications. Given the complexity of medical issues, optimal management requires a large network of health care providers; treatment decisions must address both tumor control and potential side effects of the therapy. Current treatment strategies often fail to induce sustained tumor regression and many children require several lines of therapy, highlighting the need for novel therapies. Here, we review the current management of PLGG and discuss how new molecular targets--in particular alterations of the Ras/MAPK pathway--are rapidly changing our approach to PLGG.

Statistics

Citations

Dimensions.ai Metrics
7 citations in Web of Science®
4 citations in Scopus®
1 citation in Microsoft Academic
Google Scholar™

Altmetrics

Downloads

2 downloads since deposited on 23 Jan 2017
1 download since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Children's Hospital Zurich > Medical Clinic
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:April 2016
Deposited On:23 Jan 2017 16:31
Last Modified:02 Feb 2018 11:37
Publisher:Georg Thieme Verlag
ISSN:0174-304X
OA Status:Closed
Publisher DOI:https://doi.org/10.1055/s-0035-1570491
PubMed ID:26764564

Download